Kite Pharma (KITE), a new addition to RMi’s list of companies, is a clinical-stage biopharmaceutical company focused on development and commercialization of cancer immunotherapy products designed to harness a patient’s own immune system to eradicate cancer cells. It is developing a pipeline of product candidates for the treatment of advanced solid and hematological malignancies using its therapeutic platform – engineered Autologous Cell Therapy (eACT™) – in which a patient’s own T cells, or white blood cells, are engineered to recognize and destroy their cancer. The patient’s immune system, particularly T cells, plays a critical role in identifying and killing cancer cells. KITE’s eACT™ technology involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs), or T cell receptors (TCRs). Its technology has been developed in part through collaboration with the National Cancer Institute, Surgery Branch through a cooperative research and development agreement (CRADA).
October 4, 2017
RegMed Investors’ (RMi) closing bell; momentum shifted for the oversold
October 3, 2017
RegMed Investors’ (RMi) closing bell; big dip after first hour of the session
October 2, 2017
RegMed Investors’ (RMi) closing bell; the month starts on a good note
September 29, 2017
RegMed Investors’ (RMi) closing bell; the month and quarter close positive
September 28, 2017
RegMed Investors’ (RMi) closing bell; this dip needed to be bought
September 27, 2017
RegMed Investors’ (RMi) closing bell; Yippee-Ki-Yay
September 26, 2017
RegMed Investors’ (RMi) closing bell; just when some thought it was safe to enter the sector …
September 25, 2017
RegMed Investors’ (RMi) closing bell; be careful for the upside you’ve wished for
September 22, 2017
RegMed Investors’ (RMi) closing bell; sector gets downsized again
September 21, 2017
RegMed Investors’ (RMi) closing bell; bowling for strikes, it’s all in the approach
35 companies, 1 interpreter!
Insight, foresight and recommendation
Kite Pharma (KITE) – KITE announced that four presentations relating to its clinical programs will be delivered at the upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Data presented included results from Kite’s SCHOLAR-1 study, the first and largest meta-analysis of outcomes in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL). Patients with chemorefractory DLBCL have not responded to prior treatment with chemotherapy or have relapsed within a year after autologous stem cell transplantation. Data from a P1-2a study evaluating anti-CD19 CAR T cell therapy after low-dose chemotherapy in people with advanced lymphoma was presented in a Late-Breaking Abstract oral session by James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI) Center for Cancer Research. This study is being conducted as part of a Cooperative Research and Development Agreement (CRADA) between KITE and the NCI. KITE also provided an update on patients with chemorefractory aggressive NHL from the P1 portion of the ZUMA-1 study and present a poster on the study design of ZUMA-4, an ongoing P1/2 study of KTE-C19 in children and young adults with previously treated acute lymphoblastic leukemia. In Q1/16, KITE announced a partnership with Genentech (ROCHE -- ROCHG.VX) to study its KTE-C19 in combination with the checkpoint inhibitor atezolizumab. KITE expects to initiate a P 1b/2 combination study in patients with chemorefractory diffuse large B cell lymphoma in the second half of 2016. KITE also entered into a new Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Experimental Transplantation and Immunology Branch. A P1 study of human anti-CD19 chimeric antigen receptor for treating B-cell malignancies is currently ongoing. KITE reported a Q1/16 net loss of -$43.9 M, or -$0.90 per share, compared to a net loss of -$15.1 M or -$0.36 per share for Q1/15. RECOMMENDATION: BUY
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors